Evidence map›Paper›PMID 27444931›Full record

ArticleCirculation2016

Identifying Low-Abundance Biomarkers: Aptamer-Based Proteomics Potentially Enables More Sensitive Detection in Cardiovascular Diseases.

Anthony Gramolini, Edward Lau, Peter P Liu

Abstract readEditorialComment
PubMed Publisher
In one paragraph

Article in Circulation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Precision Medicine.Circulation · 2018
    Article
  13. Review
  14. Proteomics Research in Cardiovascular Medicine and Biomarker Discovery.Journal of the American College of Cardiology · 2016
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Anthony GramoliniFrom Department of Physiology, Ted Rogers Centre for Heart Research, University of Toronto, Canada (A.G., P.P.L.); NIH BD2K Center of Excellence in Biomedical Computing, Department of Physiology, UCLA David Geffen School of Medicine, Los Angeles, CA (E.L.); and University of Ottawa Heart Institute, Departments of Medicine & Cellular Molecular Medicine, University of Ottawa, Canada (P.P.L.).
Edward LauFrom Department of Physiology, Ted Rogers Centre for Heart Research, University of Toronto, Canada (A.G., P.P.L.); NIH BD2K Center of Excellence in Biomedical Computing, Department of Physiology, UCLA David Geffen School of Medicine, Los Angeles, CA (E.L.); and University of Ottawa Heart Institute, Departments of Medicine & Cellular Molecular Medicine, University of Ottawa, Canada (P.P.L.). peter.liu@utoronto.ca pliu@ottawaheart.ca edward.lau@me.com.
Peter P LiuFrom Department of Physiology, Ted Rogers Centre for Heart Research, University of Toronto, Canada (A.G., P.P.L.); NIH BD2K Center of Excellence in Biomedical Computing, Department of Physiology, UCLA David Geffen School of Medicine, Los Angeles, CA (E.L.); and University of Ottawa Heart Institute, Departments of Medicine & Cellular Molecular Medicine, University of Ottawa, Canada (P.P.L.). peter.liu@utoronto.ca pliu@ottawaheart.ca edward.lau@me.com.

Funding

CIHR
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BiomarkersProteomicsBiomarkers, TumorCardiovascular DiseasesHumansBiomarkersBiomarkers, Tumorbiomarkerscohort studiesdiagnosisEditorialsprognosisproteomics

Identifiers

PMID27444931

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.